Tu HY - Search Results

1

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.

Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, Chaft JE, Jayakumaran G, Rose Brannon A, Benayed R, Zehir A, Donoghue M, Schultz N, Chakravarty D, Kundra R, Madupuri R, Murciano-Goroff YR, Tu HY, Xu CR, Martinez A, Wilhelm C, Galle J, Daly B, Yu HA, Offin M, Hellmann MD, Lito P, Arbour KC, Zauderer MG, Kris MG, Ng KK, Eng J, Preeshagul I, Victoria Lai W, Fiore JJ, Iqbal A, Molena D, Rocco G, Park BJ, Lim LP, Li M, Tong-Li C, De Silva M, Chan DL, Diakos CI, Itchins M, Clarke S, Pavlakis N, Lee A, Rekhtman N, Chang J, Travis WD, Riely GJ, Solit DB, Gonen M, Rusch VW, Rimner A, Gomez D, Drilon A, Scher HI, Shah SP, Berger MF, Arcila ME, Ladanyi M, Levine RL, Shen R, Razavi P, Reis-Filho JS, Jones DR, Rudin CM, Isbell JM, Li BT. Jee J, et al. Among authors: tu hy. Nat Med. 2022 Nov;28(11):2353-2363. doi: 10.1038/s41591-022-02047-z. Epub 2022 Nov 10. Nat Med. 2022. PMID: 36357680 Free PMC article.

2

Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Lei YY, Yang JJ, Zhang XC, Zhong WZ, Zhou Q, Tu HY, Tian HX, Guo WB, Yang LL, Yan HH, Chen HJ, Xie Z, Su J, Han JF, Wu YL. Lei YY, et al. Among authors: tu hy. Clin Lung Cancer. 2016 May;17(3):223-31. doi: 10.1016/j.cllc.2015.09.002. Epub 2015 Sep 21. Clin Lung Cancer. 2016. PMID: 26454342

3

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.

Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ. Lou NN, et al. Among authors: tu hy. Oncotarget. 2016 Oct 4;7(40):65185-65195. doi: 10.18632/oncotarget.11218. Oncotarget. 2016. PMID: 27533086 Free PMC article.

4

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.

Zhou Q, Yang JJ, Chen ZH, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, Yang XN, Wu YL. Zhou Q, et al. Among authors: tu hy. J Hematol Oncol. 2016 Sep 13;9(1):86. doi: 10.1186/s13045-016-0316-8. J Hematol Oncol. 2016. PMID: 27619632 Free PMC article. Clinical Trial.

5

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.

Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH, Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, Zhang YC, Niu FY, Wu YL. Ke EE, et al. Among authors: tu hy. J Thorac Oncol. 2017 Sep;12(9):1368-1375. doi: 10.1016/j.jtho.2017.05.018. Epub 2017 May 30. J Thorac Oncol. 2017. PMID: 28576746 Free article.

6

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells.

Jiang BY, Li YS, Guo WB, Zhang XC, Chen ZH, Su J, Zhong WZ, Yang XN, Yang JJ, Shao Y, Huang B, Liu YH, Zhou Q, Tu HY, Chen HJ, Wang Z, Xu CR, Wang BC, Wu SY, Gao CY, Zhang X, Wu YL. Jiang BY, et al. Among authors: tu hy. Clin Cancer Res. 2017 Sep 15;23(18):5480-5488. doi: 10.1158/1078-0432.CCR-17-0047. Epub 2017 Jun 12. Clin Cancer Res. 2017. PMID: 28606923

7

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.

Dong ZY, Zhang JT, Liu SY, Su J, Zhang C, Xie Z, Zhou Q, Tu HY, Xu CR, Yan LX, Li YF, Zhong WZ, Wu YL. Dong ZY, et al. Among authors: tu hy. Oncoimmunology. 2017 Jul 26;6(11):e1356145. doi: 10.1080/2162402X.2017.1356145. eCollection 2017. Oncoimmunology. 2017. PMID: 29147605 Free PMC article.

8

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL. Tu HY, et al. Lung Cancer. 2017 Dec;114:96-102. doi: 10.1016/j.lungcan.2017.11.005. Epub 2017 Nov 7. Lung Cancer. 2017. PMID: 29173773 Review.

9

Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

Kang J, Chen HJ, Zhang XC, Su J, Zhou Q, Tu HY, Wang Z, Wang BC, Zhong WZ, Yang XN, Chen ZH, Ding Y, Wu X, Wang M, Fu JG, Yang Z, Zhang X, Shao YW, Wu YL, Yang JJ. Kang J, et al. Among authors: tu hy. Thorac Cancer. 2018 Sep;9(9):1093-1103. doi: 10.1111/1759-7714.12791. Epub 2018 Jul 6. Thorac Cancer. 2018. PMID: 29978950 Free PMC article.

10

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

Chen RL, Zhao J, Zhang XC, Lou NN, Chen HJ, Yang X, Su J, Xie Z, Zhou Q, Tu HY, Zhong WZ, Yan HH, Guo WB, Wu YL, Yang JJ. Chen RL, et al. Among authors: tu hy. BMC Cancer. 2018 Nov 26;18(1):1171. doi: 10.1186/s12885-018-5078-y. BMC Cancer. 2018. PMID: 30477470 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

207 results

Search Page